GPX4 and ocular melanoma: In addition, the GPX4 activity by ELISA was further confirmed, which also showed that CUR-OM-MSCs produce significantly more promotion than OM-MSCs alone treatment (Fig. 3M; 17.251 ± 0.282 vs 12.040 ± 0.190, p < 0.001).